Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMVAC Vaccine for Placental Malaria
NCT02647489Phase 1Completed
- Sponsor
- University Hospital Tübingen
- Start
- May 2016
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PAMVAC in Placental Malaria (PM) (11 arms), sponsored by University Hospital Tübingen. Primary endpoint: Number and grade of adverse events at 1.5 years. Started May 2016; status: completed.
02
Drugs
PAMVAC
03
Conditions
Placental Malaria (PM)
Beyond the preview
Go deeper on NCT02647489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647489.